191 related articles for article (PubMed ID: 8726415)
41. Proliferation of peripheral lymphocytes to interleukin-2 and interleukin-4 after marrow transplantation.
Klingemann HG; Kohn FR; Phillips GL
Eur Cytokine Netw; 1991; 2(2):131-6. PubMed ID: 1813016
[TBL] [Abstract][Full Text] [Related]
42. Specific inhibition of OKT3-driven T-cell mitogenesis by an anti HLA-class I monoclonal antibody.
Beckman I; Xiaoning X; Bradley J
Immunology; 1988 Nov; 65(3):373-8. PubMed ID: 3264808
[TBL] [Abstract][Full Text] [Related]
43. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism.
Van Wauwe JP; Goossens JG; Beverley PC
J Immunol; 1984 Jul; 133(1):129-32. PubMed ID: 6327822
[TBL] [Abstract][Full Text] [Related]
44. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
45. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck.
Dadian G; Riches PG; Henderson DC; MacLennan K; Lorentzos A; Moore J; Hobbs JR; Gore ME
Eur J Cancer B Oral Oncol; 1993 Jan; 29B(1):29-34. PubMed ID: 8180573
[TBL] [Abstract][Full Text] [Related]
46. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
47. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
48. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
50. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
51. Role of interleukin 2 receptor beta chain in initiating anti-CD3 and interleukin 2-induced proliferation of human resting T cells.
Moiré N; Calvo CF; Métivier D; Perrot JY; Vaquero C; Hatakeyama M; Senik A
Eur J Immunol; 1990 Sep; 20(9):1981-7. PubMed ID: 2145171
[TBL] [Abstract][Full Text] [Related]
52. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.
Kon OM; Sihra BS; Loh LC; Barkans J; Compton CH; Barnes NC; Larché M; Kay AB
Eur Respir J; 2001 Jul; 18(1):45-52. PubMed ID: 11510804
[TBL] [Abstract][Full Text] [Related]
53. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
54. Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell proliferation.
De Felice M; Turco MC; Giarrusso PC; Corbo L; Pizzano R; Martinelli V; Ferrone S; Venuta S
J Immunol; 1987 Oct; 139(8):2683-9. PubMed ID: 2443568
[TBL] [Abstract][Full Text] [Related]
55. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
56. Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression.
Lin J; Gettys TW; Qin L; Chavin KD; Yang Q; Ding Y; Punch JD; Bromberg JS
Pathobiology; 1995; 63(4):175-87. PubMed ID: 8866788
[TBL] [Abstract][Full Text] [Related]
57. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
58. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
59. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
60. CD8+/DR+/CD25--T-lymphocytes associated with marrow graft failure.
Voltarelli JC; Przepiorka D; Shankar P; Kopecky K; Martin PJ; Torok-Storb B
Bone Marrow Transplant; 1989 Nov; 4(6):647-52. PubMed ID: 2573398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
